FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study

Katharina Pomej, Adrian Frick, Bernhard Scheiner, Maximilian Baumgartner, Klaus G. Schmetterer, Carlos S. Reyna-Blanco, Lorenz Balcar, Larissa Pajancic, Abelina Kreuter, Joana Séneca, Bela Hausmann, Thomas Köcher, Melanie Prinzensteiner, Katharina Lampichler, Nataliya Rohr-Udilova, Adrija Chakrabarty, Anton Klotz, Annika C. Lampl, Kerstin Zinober, Katharina Regnat, Michael Trauner, David Berry, Dietmar Tamandl, Thomas Vogl, Christoph Gasche, Matthias Pinter

Open source

DOI: 10.1038/s41467-026-78219-z
Published: 2026-10-07
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-78219-z,
  title = {FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study},
  author = {Katharina Pomej and Adrian Frick and Bernhard Scheiner and Maximilian Baumgartner and Klaus G. Schmetterer and Carlos S. Reyna-Blanco and Lorenz Balcar and Larissa Pajancic and Abelina Kreuter and Joana Séneca and Bela Hausmann and Thomas Köcher and Melanie Prinzensteiner and Katharina Lampichler and Nataliya Rohr-Udilova and Adrija Chakrabarty and Anton Klotz and Annika C. Lampl and Kerstin Zinober and Katharina Regnat and Michael Trauner and David Berry and Dietmar Tamandl and Thomas Vogl and Christoph Gasche and Matthias Pinter},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-78219-z},
  url = {https://doi.org/10.1038/s41467-026-78219-z}
}

RIS

TY  - JOUR
TI  - FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study
AU  - Katharina Pomej
AU  - Adrian Frick
AU  - Bernhard Scheiner
AU  - Maximilian Baumgartner
AU  - Klaus G. Schmetterer
AU  - Carlos S. Reyna-Blanco
AU  - Lorenz Balcar
AU  - Larissa Pajancic
AU  - Abelina Kreuter
AU  - Joana Séneca
AU  - Bela Hausmann
AU  - Thomas Köcher
AU  - Melanie Prinzensteiner
AU  - Katharina Lampichler
AU  - Nataliya Rohr-Udilova
AU  - Adrija Chakrabarty
AU  - Anton Klotz
AU  - Annika C. Lampl
AU  - Kerstin Zinober
AU  - Katharina Regnat
AU  - Michael Trauner
AU  - David Berry
AU  - Dietmar Tamandl
AU  - Thomas Vogl
AU  - Christoph Gasche
AU  - Matthias Pinter
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-78219-z
UR  - https://doi.org/10.1038/s41467-026-78219-z
ER  -

APA

Pomej, K., Frick, A., Scheiner, B., Baumgartner, M., Schmetterer, K. G., Reyna-Blanco, C. S., Balcar, L., Pajancic, L., Kreuter, A., Séneca, J., Hausmann, B., Köcher, T., Prinzensteiner, M., Lampichler, K., Rohr-Udilova, N., Chakrabarty, A., Klotz, A., Lampl, A. C., Zinober, K., Regnat, K., Trauner, M., Berry, D., Tamandl, D., Vogl, T., Gasche, C., & Pinter, M. (2026). FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study. Nature Communications. https://doi.org/10.1038/s41467-026-78219-z

Source records

crossref · retrieved 2026-11-07T06:56:18.591Z